Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Gewirtz

Podiatrist Park Ridge, NJ Doctor of Podiatric Medicine

NPI 1396720769 CMS profile 688211

74 Pascack Rd, Ste 6, Park Ridge, NJ 07656

Open in the dashboard

General payments

$23,936

69 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Gewirtz of Park Ridge, NJ is reported in the CMS Open Payments database as having received $23,936 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,470 10
2024 General $619 9
2023 General $9,027 14
2022 General $10,902 20
2021 General $387 6
2020 General $235 3
2019 General $296 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Gewirtz
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Jeffrey Gewirtz were reported at $2,470. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Jeffrey Gewirtz Podiatrist median Middle half National median
2019 $296 $196 $72–$601 $163
2020 $235 $118 $38–$335 $114
2021 $387 $169 $57–$573 $132
2022 $10,902 $220 $74–$782 $149
2023 $9,027 $208 $71–$635 $160
2024 $619 $237 $87–$681 $164
2025 $2,470 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $19,122 26 payments
  2. Orpyx Medical Technologies Inc. $1,872 2 payments
  3. Zimmer Biomet Holdings, Inc. $773 7 payments
  4. Kerecis Limited $679 7 payments
  5. Smith+Nephew, Inc. $204 6 payments
  6. Cepheid $172 1 payment
  7. Extremity Medical $136 2 payments
  8. PolarityTE, Inc. $127 3 payments
  9. Royal Biologics $127 1 payment
  10. GRT US Holding, Inc. $125 1 payment
  11. Other $599 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $9,375 5 payments
  2. Travel and Lodging $7,906 5 payments
  3. Food and Beverage $4,552 56 payments
  4. Consulting Fee $1,900 1 payment
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $172 1 payment
  6. Education $30 1 payment
Products named General payments · program years 2019–2025
  1. Omnia $8,473 6 payments
  2. Senza Spinal Cord Stimulator $8,378 5 payments
  3. Senza Spinal Cord Stimulator $2,272 15 payments
  4. Kerecis SurgiClose Wound Care $473 5 payments
  5. Kerecis SurgiClose Wound Care $473 5 payments
  6. Kerecis SurgiClose Wound Care $473 5 payments
  7. Kerecis GraftGuide $473 5 payments
  8. Kerecis SurgiClose Wound Care $473 5 payments
  9. CERAMENTBONE VOID FILLER $271 2 payments
  10. Kerecis Omega3 SurgiClose $206 2 payments
  11. Other $3,127 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$372,126

Medicare's payments for the services billed

Medicare patients

776

Average age 76

Services billed

10,912

424 women, 352 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 35%
Ischemic heart disease 35%
Atrial fibrillation 20%
Cancer 20%
Chronic kidney disease 19%
Depression 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record